Longitudinal Association of Remnant Cholesterol With Cognitive Decline Varies by Lipid‐Lowering Drugs: A Population‐Based Cohort Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040211 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Jianian Hua und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Hypolipidemic Agents, Cholesterol, Cognition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although the association between remnant cholesterol (RC) and cognitive impairment has been reported, the association of RC with cognitive decline remains scarce. Also, the role of lipid‐lowering therapy in the association is unclear. The study aimed to examine the longitudinal associations of RC with cognitive decline by lipid‐lowering drug use during follow‐up. Methods and Results The study used data from Wave 2 (2004–2005) to Wave 8 (2016–2017) of the ELSA (English Longitudinal Study of Ageing). Global cognitive functions at baseline (Wave 2) and during the follow‐up (Waves 3–8) were assessed by integrating 3 cognitive domains: memory capacity, semantic fluency, and orientation. Multivariate‐adjusted linear mixed models were employed to examine the longitudinal associations, with results presented as β (95% CI) in SD/year. Of the 5053 participants ultimately included, 55.4% were female and the mean age (SD) was 65.7 (9.3) years. Per 1 mmol/L increment in RC was significantly associated with a faster rate of cognitive decline ( β =−0.010 SD/year [95% CI −0.019 to −0.001]). Furthermore, we observed that association pattern between RC and cognitive decline only in the non‐lipid‐lowering drug group ( β =−0.019 SD/year [95% CI, −0.031 to −0.007]) but not in the lipid‐lowering drug group ( β =0.007 SD/year [95% CI, −0.006 to 0.020]), with a significant interaction ( P =0.015). Similar findings were observed for the 3 cognitive domains.
Conclusions
Higher baseline RC levels were associated with steeper cognitive decline. The use of lipid‐lowering drugs might mitigate this decline. These findings underscore the importance of early RC monitoring and proactive management with lipid‐lowering drugs in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China.
- Department of Obstetrics and Gynecology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China.
- Department of Cardiac Surgery, Heart Center and Beijing Key Laboratory of Hypertension Beijing Chaoyang Hospital, Capital Medical University Beijing China.
- Department of Physical Medicine and Rehabilitation The First Affiliated Hospital of Soochow University Suzhou Jiangsu China.
ORCID-Profile: Jianian Hua, Jianye Dong, Haibin Li, Qingmei Chen
Zitieren
APA
Hua, J., Dong, J., Chen, Y., Li, H., & Chen, Q. (2025). Longitudinal Association of Remnant Cholesterol With Cognitive Decline Varies by Lipid‐Lowering Drugs: A Population‐Based Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040211
Vancouver
Hua J, Dong J, Chen Y, Li H, Chen Q. Longitudinal Association of Remnant Cholesterol With Cognitive Decline Varies by Lipid‐Lowering Drugs: A Population‐Based Cohort Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040211
BibTeX
@article{Hua2025,
author = {Hua, Jianian and Dong, Jianye and Chen, Ying and Li, Haibin and Chen, Qingmei},
title = {Longitudinal Association of Remnant Cholesterol With Cognitive Decline Varies by Lipid‐Lowering Drugs: A Population‐Based Cohort Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040211}
}
EUVIMED